MTD
Mettler Toledo
$1,430.30
▲ 0.6%Updated Aug 7, 11:30 AM ET
MTD at a glance — five pillars scored 0–100 from real filed financials.
Overall: Neutral · 52/100. A wider, greener shape means more pillars look healthy. Dividends scores 0 when a company pays none — that is a choice, not a flaw.
▼ Down 0.1% over the last 12 months
Market Cap
$26.44B
P/E
33.23x
Forward P/E (est.)
31.25x
ROE
1675.8%
Revenue Growth
6.8%
EPS Growth
6.3%
Profit Margin
21.4%
FCF Yield
3.9%
Debt / Equity
81.23x
ROIC
—
Interest Coverage
—
Current Ratio
1.2x
Dividend Yield
—
Implied Growth (rev. DCF)
5.6%
Rating Score
52/100
Mettler Toledo (MTD) is a large-cap company in the Life Sciences Tools & Services industry, part of the Health Care sector of the S&P 500, with a market value around $26.44B.
In its latest reported year it generated about $4.03B in revenue and $869.19M in net profit.
Our model rates MTD Neutral (52/100) on growth, profitability, financial health, and valuation. The summary below is built from its filed financials and current ratios and refreshes automatically.
Evidence of durable competitive advantage in the filed financials (10 years of history).
The filed history looks like a business competitors struggle to attack: high and steady margins, revenue that grows through cycles, and strong returns on capital.
59.5% average over the last 3 years
±1.6 pts around 58.1% across 10 years
grew in 8 of the last 9 year-over-year periods
positive in 10 of 10 years
A moat can't be proven by numbers alone — this scores the evidence a durable advantage leaves behind (pricing power, consistency, returns on capital), computed the same way for every stock. Pair it with the business overview before concluding anything.
Technical analysis reads price and volume to judge momentum and timing. It complements the fundamentals above — it does not replace them. Here is what MTD's chart says today, with each tool explained.
Trend — moving averages. A moving average is the average closing price over a window, which smooths out daily noise. MTD trades near $1,430.30, above its 50-day average ($1,180.49) and 200-day average ($1,313.60). Price above both averages, with the shorter one above the longer, is the textbook definition of an uptrend — momentum favours buyers.
Momentum — RSI. The Relative Strength Index runs 0–100 and measures how strong recent gains are versus losses. Above 70 is "overbought", below 30 "oversold". At 82 it is overbought — the recent rally is stretched and can cool off.
MACD. MACD compares two moving averages to flag shifts in momentum. Its histogram is currently positive — short-term momentum is improving.
Volatility — ATR. Average True Range is the typical daily move. MTD's is $34.02 (~2.4% of price), so swings of about that size each day are normal — handy for setting a stop that isn't too tight.
Support & resistance. Over the last month MTD found buyers near $1,113.90 (support) and sellers near $1,321.47 (resistance); its 52-week range is $1,023.05–$1,525.17. A decisive break beyond either edge often marks the next move.
Volume. The latest session traded 0.7× the 20-day average — about normal. Rising volume on up-days suggests real buying; on down-days, real selling.
Educational information to help you read a chart — not a recommendation or a forecast. It updates daily as the price and indicators change.
4Y CAGR
2.0%
Revenue moved from $2.38B in 2013 to $4.03B in 2025, a 6.0% compound annual growth rate. The most recent year grew a steady 6.8% year over year. Slower, mature growth is common for established businesses.
Gross Margin
59.4%
Operating Margin
25.8%
Net Margin
21.6%
ROE
1675.8%
Mettler Toledo keeps about 21.4% of each sales dollar as net profit, with a 59.4% gross margin and 25.8% operating margin. Return on equity is 1675.8%. Margins this wide usually signal pricing power or a cost advantage.
Total Debt
$2.09B
Net Debt
$2.02B
Net Debt / EBITDA
—
Debt / Equity
81.23x
Leverage: debt-to-equity is 81.2x, with a current ratio of 1.2x. That is elevated leverage, which raises risk if earnings or rates move against it. It carries roughly $2.09B of total debt against $69.06M of cash.
Operating CF
$955.77M
Free Cash Flow
$848.65M
FCF Margin
21.1%
In the latest year Mettler Toledo produced about $955.77M of operating cash flow and $848.65M of free cash flow after capital spending. That is a free-cash-flow yield of about 3.9% on today's price. Cash flow is what ultimately pays shareholders, so it is worth tracking over time.
P/E
33.23x
P/S
5.81x
P/B
—
EV / EBITDA
—
MTD trades at 33.2x trailing earnings (about 31.2x on estimated forward earnings), 5.8x sales. Reverse-engineering today's price implies the market expects roughly 5.6% long-term free-cash-flow growth. That is a premium multiple that needs growth to justify it.
A two-stage discounted cash flow on real SEC-filed free cash flow — the intrinsic-value anchor professional analysts triangulate from.
DCF fair value / share
$843.32
Current price
$1,430.30
Starting FCF (latest 10-K)
$848.65M
Growth, years 1–5
6.8%
Fade to terminal, years 6–10
2.5%
Discount rate
9.0%
Cash flows grow at the stage-1 rate (trailing revenue growth, capped at 20%) for five years, fade to 2.5% by year 10, and continue at that rate forever (Gordon terminal value), all discounted at 9.0%. Small changes in assumptions move the result a lot — treat this as one reference point, not a target price. Educational only, not investment advice.
Where MTD sits versus its Health Care sector peers in the S&P 500.
Bands show the middle half (25th–75th percentile) of the 83 Health Care companies in the S&P 500 — the peer-relative anchor professional comps analysis uses. Context only — not investment advice.
How MTD stacks up against its Health Care peers — valuation, profitability, and growth versus the sector median.
In the Health Care sector (324 S&P 500 companies), MTD ranks #41 of 324 by our overall rating. It trades at a premium versus the sector on earnings (33.2x P/E vs. 27.3x median) with a higher return on equity (1675.8% vs. 14.1%) and slower revenue growth (6.8% vs. 7.6%).
P/E vs sector
33.2x
median 27.3x
ROE vs sector
1675.8%
median 14.1%
Growth vs sector
6.8%
median 7.6%
Sector rank
#41
of 324 by rating
Valuation vs. quality map
The sweet spot is upper-left: more profitable (higher ROE) for a lower P/E. Dashed lines mark the sector median.
Peers are the closest Health Care companies by sub-industry and size. Sector median is across all 324 S&P 500 names in the sector. Educational, not a recommendation.
Project revenue → earnings → price. Edit the assumptions to build your own case.
2030 price target (Base Case)
$0.00 – $0.00
vs. $1,430.30 today · expected CAGR -1% – 9%
| Metric | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| Revenue | $4.31B | $4.61B | $4.93B | $5.28B | $5.65B |
| Net income | $947.81M | $1.01B | $1.09B | $1.16B | $1.24B |
| EPS | $51.27 | $54.86 | $58.70 | $62.81 | $67.21 |
| Share price (low) | $1,025.45 | $1,097.23 | $1,174.04 | $1,256.22 | $1,344.16 |
| Share price (high) | $1,691.99 | $1,810.43 | $1,937.17 | $2,072.77 | $2,217.86 |
| CAGR (low–high) | -28% / 18% | -12% / 13% | -6% / 11% | -3% / 10% | -1% / 9% |
Educational model on sample fundamentals — not a forecast or investment advice. Outputs are only as good as your assumptions.
The case for MTD:
- High net margins (21.4%) point to pricing power or efficiency.
- Strong return on equity (1675.8%) shows capital is put to work well.
The case against MTD:
- Elevated leverage (debt/equity 81.2x) adds financial risk.
- Like any single stock, it is exposed to competition, the economic cycle, and shifts in its end markets.
Valuation risk — at 33.2x earnings, disappointing results could compress the multiple.
Balance-sheet risk — debt/equity of 81.2x magnifies the impact of higher rates or weaker earnings.
Market risk — sector rotation, the economic cycle, and broad sentiment move the stock regardless of fundamentals.
On balance, the picture is mixed: Mettler Toledo is a large-cap health care business growing at a mature pace, with solid profitability, and a heavier debt load to watch. It trades at 33.2x earnings, which our model scores Neutral (52/100). Weigh this against your own goals and time horizon — this is educational information, not a recommendation.
Analyst Ratings
What 19 Wall Street analysts covering MTD recommend (August 2026). Consensus is a useful sanity check — not a substitute for your own homework.
Latest SEC Filings
MTD's most recent filings, straight from SEC EDGAR. Annual and quarterly reports are the deep dives; 8-Ks flag material events the moment they happen.
In the Idea Lab
MTD — frequently asked questions
Is MTD a good stock to buy?
We don't give buy or sell advice. Our model rates Mettler Toledo Neutral (52/100) based on its growth, profitability, financial health, and valuation — use that as a research starting point and make your own decision.
What is MTD's rating on The Stocks School?
Mettler Toledo currently scores 52/100 (Neutral) on our transparent model, which weighs real fundamentals: growth, margins, returns on capital, balance-sheet strength, and valuation.
How our ratings work →Where does MTD's data come from?
Live price data plus real fundamentals and 5-year financials pulled directly from Mettler Toledo's SEC filings — refreshed automatically, not hand-entered.
How is the 5-year projection for MTD calculated?
It's a scenario model: it grows revenue at an assumed rate, applies a profit margin and a valuation multiple, and shows the resulting share-price range. The assumptions are yours to change — it's a tool for thinking, not a prediction.
Is this MTD analysis financial advice?
No. Everything on this page is educational research, not financial advice or a recommendation to buy or sell MTD. Always do your own research and consider a licensed professional.
Data notice. Fundamentals and financial statements are sourced from company filings (SEC EDGAR) and market-data providers; prices and market caps refresh on trading days and may be delayed. Ratings, projections, technical signals, and written summaries are model- or rule-generated for education and may simplify or lag the latest filings.
Not advice. Nothing on this page is investment advice or a recommendation to buy, hold, or sell any security. Do your own research and consult a licensed financial professional before investing.